Widcef-LB Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Lactobacillus 2.5 billion spores, designed for the effective treatment of bacterial infections while maintaining gastrointestinal flora balance. Cefixime, a third-generation cephalosporin antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, making it effective against various Gram-positive and Gram-negative pathogens responsible for respiratory tract infections, urinary tract infections, otitis media, and uncomplicated gonorrhea. The inclusion of Lactobacillus spores serves as a probiotic adjunct to restore and preserve the natural intestinal microflora, which may be disrupted during antibiotic therapy, thereby reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Widcef-LB is indicated for patients requiring antimicrobial therapy with concurrent probiotic support to enhance treatment tolerability and minimize adverse effects on gut health. The tablet should be administered as per the prescribed dosage regimen, and patients are advised to complete the full course to prevent resistance development. Caution is warranted in individuals with known hypersensitivity to cephalosporins or probiotics. This combination therapy offers a synergistic approach to managing infections while supporting gastrointestinal well-being.